Steroid-toxicity Insights Roundup
As we know, most physicians recognize that steroids have been harmful to patients over the 75 years of their use. Less discussed is that steroids have been harmful to #ClinicalResearch as well and can delay the development of effective new therapies.
Most subjects enrolled in clinical trials of new therapies for autoimmune diseases must be stable enough to meet the inclusion criteria. This means that they often need to be on glucocorticoids. Maintenance doses of steroids are often so powerful they can mask the impact of novel therapies and can prevent beneficial new drugs from further development.
To find out more, read our recent interview with Andreas Reiff, MD, senior vice president and global therapeutic area head for inflammation/immunology at Parexel.
Andreas Reiff, MD is the senior vice president and global therapeutic area head for inflammation/immunology at Parexel. He is a board-certified rheumatologist and pediatrician, has extensive experience in drug development, and holds several academic and advisory roles.
Steroid-toxicity presents a bigger problem for children than it does for adults with SLE. Treat-to-target can help improve outcomes.?
Recent studies support the use of shorter tapers in combination with steroid-sparing agents to induce and maintain remission in GCA patients.
Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize treatment of inflammatory diseases and improve the quality of patient care around the world.
Learn more at steritas.com.
Sincerely,
Martha Stone
CEO, Steritas